PORTSMOUTH, N.H., Jan. 6, 2026 /PRNewswire/ — Medispend and RLDatix Life Sciences today announced the successful completion of their merger, creating a unified PORTSMOUTH, N.H., Jan. 6, 2026 /PRNewswire/ — Medispend and RLDatix Life Sciences today announced the successful completion of their merger, creating a unified

Medispend and RLDatix Life Sciences Complete Merger, Uniting Under the Medispend Brand to Create The Leading Life Sciences Compliance Software-as-a-Service Provider

2026/01/06 23:01
2분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

PORTSMOUTH, N.H., Jan. 6, 2026 /PRNewswire/ — Medispend and RLDatix Life Sciences today announced the successful completion of their merger, creating a unified organization that will operate under the Medispend name. The combined company offers a comprehensive suite of enterprise software and services for global regulatory and commercial compliance, medical affairs, field enablement and revenue management solutions designed to empower life sciences companies to grow their business compliantly.

While the company will continue under the Medispend name, the merger marks a significant evolution of the brand. Medispend is introducing a refreshed visual identity, including a new logo, color palette, and emblem, to reflect its expanded capabilities, forward-looking vision, and commitment to innovation.

The unified Medispend is positioned to become a single, trusted vendor providing the most comprehensive suite of life sciences compliance, stakeholder engagement, medical affairs, field enablement, and revenue management solutions in the industry. By combining the strengths of both organizations, Medispend now offers an expanded product portfolio supported by advanced technology, enhanced analytics, and scalable managed services designed to meet the evolving needs of global life sciences organizations.

“This merger represents a pivotal moment for our customers and the industry,” said Leigh Powell, executive chairman of Medispend. “By bringing together RLDatix Life Sciences and Medispend under one brand, we are accelerating our ability to deliver innovative, purpose-built solutions that help customers reduce risk, streamline operations, and confidently grow their business in an increasingly complex regulatory environment.”

Christopher Gingras, president of Medispend, said, “The new Medispend brand reflects a clear future vision, which includes our continued investment in innovative technology, expanded managed services, and a relentless focus on customer success.”

Existing customers will continue to receive uninterrupted service and support, while benefiting from the expanded capabilities and resources of the combined organization.

About Medispend:

Medispend is a global leading provider of SaaS solutions that deliver secure, scalable and intuitive cloud-based software enabling life sciences organizations to grow their business compliantly. More than 400 pharmaceutical, biotech and medical technology companies from around the world rely on Medispend to reduce compliance risk, improve customer engagements, optimize operations and make data driven decisions. Our mission is to help customers scale confidently and compliantly in an increasingly complex healthcare environment. For more information, visit www.medispend.com.

Media Contact:
Seth Houston
Chief Commercial Officer
shouston@medispend.com
(215) 779-2415

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medispend-and-rldatix-life-sciences-complete-merger-uniting-under-the-medispend-brand-to-create-the-leading-life-sciences-compliance-software-as-a-service-provider-302652858.html

SOURCE Medispend

시장 기회
Humanity 로고
Humanity 가격(H)
$0.09471
$0.09471$0.09471
-2.05%
USD
Humanity (H) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!